Clinical trials: Uterus Cancer
Cervical Cancer
Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer
This study is an open-label, multicenter, multinational, two-arm, parallel randomized Phase 3 study evaluating the efficacy and safety of S-1+Cisplatin versus single-agent Cisplatin in patients with stage IVB, recurrent or…
- Trial name
- NCT00770874
- Testing
- S-1 + Cisplatin (arm A), Cisplatin (arm B)
- Where
- 4 sites in Japan, South Korea and 1 more
- Volunteers
- 375 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial is studying how well selumetinib works in treating patients with recurrent or persistent endometrial cancer that has come back or is persistent.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
- Trial name
- NCT01011933
- Testing
- Diagnostic Laboratory Biomarker Analysis, Selumetinib
- Where
- 72 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
The purpose of the trial is to evaluate the safety, determine the recommended Phase 2 dose (RP2D), and assess preliminary clinical activity of GEN1044 in patients with solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT04424641
- Testing
- GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 48 people
- Sponsor
- Genmab
Cervix Cancer, Cervix Intraepithelial Neoplasia Grade 3
Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya
This study investigates the pharmacokinetics of Artesunate (AS) and dihydroartemisinin (DHA), the active metabolite of Artesunate, following intravaginal use at the dosing and frequency being studied for cervical precancer…
- Conditions
- Cervix Cancer, Cervix Intraepithelial Neoplasia Grade 3, Cervix; Intraepithelial Neoplasia, Grade I, Cervix; Intraepithelial Neoplasia, Grade II
- Trial name
- NCT06263582
- Testing
- Artesunate pessary, blood draws for pharmacokinetics of the study drug
- Where
- Kenya
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cervical Cancer
Promoting Cervical Cancer Screening for Emergency Department Patients
The purpose of this study is to learn methods to encourage women to get recommended cervical cancer screening. Cervical cancer screening is an important part of cervical cancer prevention.
- Trial name
- NCT03483610
- Testing
- Provider Referral, Text Messaging
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- University of Rochester
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
This randomized phase II trial studies paclitaxel, carboplatin, and bevacizumab or paclitaxel, carboplatin, and temsirolimus or ixabepilone, carboplatin, and bevacizumab to see how well they work in treating patients with stage…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT00977574
- Testing
- Bevacizumab, Carboplatin, Ixabepilone
- Where
- 230 sites in United States
- Volunteers
- 349 people
- Sponsor
- National Cancer Institute (NCI)
Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
To evaluate the tolerability and safety of axalimogene filolisbac 1 x 10^10 colony forming units (cfu) administered with prophylactic premedication in repeating 3-dose study cycles in women with persistent, metastatic, or…
- Conditions
- Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer, Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma
- Trial name
- NCT02164461
- Testing
- Axalimogene filolisbac
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Advaxis, Inc.
Mixed Mullerian Tumors of the Uterus
Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus
The purpose of this research study is to determine the feasibility and safety of giving the combination of oxaliplatin and gemcitabine followed by radiation therapy and to learn whether or not this drug combined with radiation…
- Trial name
- NCT00476086
- Testing
- Gemcitabine, Oxaliplatin, Radiation
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Cervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion
IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3
This randomized phase II trial studies how well an IRX-2 Regimen works in treating women with cervical squamous intraepithelial neoplasia 3 or squamous vulvar intraepithelial neoplasia 3.
- Trial name
- NCT03267680
- Testing
- Cyclophosphamide, Indomethacin, IRX-2
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Southern California
Endometrial Carcinoma
Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer
The purpose of this study is to find out whether the addition of a drug called Avastin (avastin) to the two-drug combination of carboplatin and paclitaxel shrinks tumors better than the two-drug combination alone in the treatment…
- Trial name
- NCT00879359
- Testing
- carboplatin, paclitaxel, and bevacizumab
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
This phase II trial is studying how well ABI-007 works in treating patients with persistent or recurrent cervical cancer. Drugs used in chemotherapy, such as ABI-007, work in different ways to stop the growth of tumor cells…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT00309959
- Testing
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Laboratory Biomarker Analysis
- Where
- 26 sites in United States
- Volunteers
- 37 people
- Sponsor
- Gynecologic Oncology Group
Infections, Papillomavirus, Papillomavirus Vaccines
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
HPV infection has been established as a necessary cause of cervical cancer. GSK Biologicals has developed an HPV-16/18 L1 VLP AS04 vaccine (Cervarix TM) which targets the 2 most common oncogenic HPV types (HPV-16 and HPV-18)…
- Trial name
- NCT00423046
- Testing
- GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM), Gardasil ® (Merck & Co. Inc)
- Where
- 40 sites in United States
- Volunteers
- 1,106 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT03245736
- Testing
- Tisotumab Vedotin
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 5 people
- Sponsor
- Seagen Inc.
Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
This randomized phase III trial studies carboplatin and paclitaxel to see how well they work with or without cisplatin and radiation therapy in treating patients with stage I-IVA endometrial cancer.
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7
- Trial name
- NCT00942357
- Testing
- Carboplatin, Cisplatin, Internal Radiation Therapy
- Where
- 670 sites in United States, Canada and 1 more
- Volunteers
- 813 people
- Sponsor
- Gynecologic Oncology Group
Cervical Cancer, Genital Warts
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
The primary purpose of the study is to determine if GARDASIL™ (V501) is able to prevent cervical cancer.
- Trial name
- FUTURE II (NCT00092534)
- Testing
- Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
- Volunteers
- 12,167 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent Endometrial Cancer
Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
Primary Objectives: To assess the antitumor activity (proportion of objective response by RECIST 1.1 criteria) of pembrolizumab with objective tumor response in patients with persistent, recurrent or metastatic endometrial cancer…
- Trial name
- NCT02899793
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Yale University
Cervical Cancer
AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer
This study tested how well and how safely the drug tislelizumab, given either alone or with another drug called ociperlimab (BGB-A1217), worked in people with cervical cancer that had come back or spread after previous…
- Trial name
- NCT04693234
- Testing
- Tislelizumab, Ociperlimab
- Where
- 68 sites in Bulgaria, China and 6 more
- Volunteers
- 178 people
- Sponsor
- BeiGene
Leiomyoma
Superior Hypogastric Nerve Block for Pain Control Post-uterine Fibroid Embolization
Uterine fibroid embolization (UFE) is now an accepted treatment of uterine fibroids. However the procedure is often very painful and, in many centres, patients are admitted overnight with patient controlled analgesic (PCA) pumps…
- Trial name
- NCT02270255
- Testing
- Superior hypogastric nerve block, 0.75% Ropivacaine, Subcutaneous injection
- Where
- Canada
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Ovarian Neoplasm, Uterine Neoplasm
Supportive Programs for Supporting Optimal Recovery in Participants Undergoing Gynecological Surgery
This trial studies how well two different supportive programs work in supporting optimal recovery in participants undergoing gynecological surgery.
- Trial name
- NCT03681405
- Testing
- Informational Intervention, Questionnaire Administration, Telephone-Based Intervention
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Wake Forest University Health Sciences
Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
This phase II trial studies the effect of onapristone and anastrozole in treating patients with hormone receptor positive endometrial cancer that has not responded to previous treatment (refractory).
- Conditions
- Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Endometrial Clear Cell Adenocarcinoma, Refractory Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT04719273
- Testing
- Extended-release Onapristone, Anastrozole, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Thomas Jefferson University